Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 15 clinical trials
Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE) (BladderGATE)

-specific CD8 T-cells, impairing cytokine production and diminishing the toxicity of activated T-cells. PD-L1 expression by immunohistochemistry using the Ventana SP142 assay on tumor-infiltrating immune

bladder cancer
carcinoma
carcinoma in situ
transurethral resection
tumor cells
  • 1 views
  • 21 Mar, 2022
Preoperative CRT With Capecitabine Temozolomide in Patients With LARC

This is a prospective biomarker-stratified, randomised phase II study of preoperative CRT with temozolomide plus capecitabine in patients with locally advanced rectal cancer. The primary endpoint is pathologic complete response rates defined as total regression of the primary tumor. For each cohort of MGMT hypermethylated versus MGMT unmethylated, patients will …

  • 26 views
  • 27 Jan, 2021
  • 1 location
5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.

An upfront-intensified treatment combining all the three active cytotoxic agents in metastatic colorectal cancer (mCRC) including fluoropyrimidines, oxaliplatin, irinotecan (FOLFOXIRI) plus antiangiogenic blockade with bevacizumab significantly improved survival. No biomarkers are available for predicting sensitivity/resistance to single chemotherapeutic drugs, the simultaneous delivery of all active chemotherapeutic agents might overcome resistance …

  • 3 views
  • 23 Apr, 2022
  • 1 location
A Randomized, Double-Blinded, Pilot Trial of Neoadjuvant Checkpoint Inhibition Followed by Combination Adjuvant Checkpoint Inhibition in Children and Young Adults With Recurrent or Progressive High Grade Glioma (HGG)

This phase I trial studies the side effects of nivolumab and ipilimumab before and after surgery in treating children and young adults with high grade glioma that has come back (recurrent) or is increasing in scope or severity (progressive). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help …

platelet count
ipilimumab
monoclonal antibodies
MRI
interferon
  • 72 views
  • 20 Sep, 2022
  • 20 locations
Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression

/or progesterone) expression by immunohistochemistry (IHC).

who 2017
pancreatic net
platelet count
neutrophil count
measurable disease
  • 0 views
  • 05 May, 2022
  • 1 location
HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors

or young adult with a refractory or recurrent CNS tumor will have their tumor tested for HER2 expression by immunohistochemistry (IHC) at their home institution or at Seattle Children's Hospital. If

cns disease
erbb2
viral therapy
MRI
central nervous system tumor
  • 68 views
  • 17 Mar, 2022
  • 1 location
Rituximab and Pegfilgrastim in Treating Patients With Non-Hodgkin's Lymphoma

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Pegfilgrastim may stimulate the immune system in different ways and stop cancer …

cancer
monoclonal antibodies
rituximab
  • 46 views
  • 07 Nov, 2020
  • 1 location
Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer

This phase II trial studies the effect of onapristone and anastrozole in treating patients with hormone receptor positive endometrial cancer that has not responded to previous treatment (refractory). Progesterone and estrogen are hormones that can cause the growth of endometrial cancer cells. Onapristone blocks the use of progesterone by the …

adenocarcinoma
carcinoma
hysterectomy
endometrioid adenocarcinoma
anticoagulant
  • 5 views
  • 04 Oct, 2022
  • 2 locations
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

This early phase I trial studies the effect of pembrolizumab and lenvatinib in treating patients with gastroesophageal adenocarcinoma that has spread to other places in the body (advanced/metastatic) or cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the …

  • 0 views
  • 07 Mar, 2022
  • 1 location
Examining Bioactivity of PVSRIPO in Invasive Breast Cancer

This is a pilot study to examine PVSRIPO bioactivity in tumor tissue after intratumoral administration of PVSRIPO in women with invasive breast cancer.

progesterone receptor
residual tumor
progesterone
mammogram
estrogen
  • 1 views
  • 13 Feb, 2022
  • 1 location